Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 19, 2022 | Series C | $300M | 12 | — | — | Detail |
Jan 12, 2021 | Series B | $230M | 6 | Alaska Permanent Fund SoftBank Vision Fund | — | Detail |
May 7, 2020 | Seed | $2.70M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Abu Dhabi Investment Authority | — | Series C |
Alaska Permanent Fund | — | Series C |
Altitude Life Science Ventures | — | Series C |
Artis Ventures (AV) | — | Series C |
Cormorant Asset Management | — | Series C |
Flagship Pioneering | — | Series C |
Hanwha Impact Partners | — | Series C |
Longevity Vision Fund | — | Series C |
March Capital | — | Series C |
SALT Fund | — | Series C |